Use of oral contraceptives and endometrial cancer risk (Sweden)

被引:94
作者
Weiderpass, E [1 ]
Adami, HO
Baron, JA
Magnusson, C
Lindgren, A
Persson, I
机构
[1] Karolinska Inst, Dept Med Epidemiol, SE-17177 Stockholm, Sweden
[2] Harvard Univ, Dept Epidemiol, Boston, MA 02115 USA
[3] Harvard Univ, Harvard Ctr Canc Prevent, Boston, MA 02115 USA
[4] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA
[5] Falun Hosp, Dept Pathol, Falun, Sweden
关键词
combined oral contraceptives; endometrial neoplasms; Sweden;
D O I
10.1023/A:1008945721786
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To estimate the magnitude and persistence of the protective effect of use of combined oral contraceptives (COCs) and endometrial cancer risk. Methods: We performed a nation-wide, population-based case-control study among postmenopausal women aged 50-74 years in Sweden, which included 709 subjects with incident, histopathologically verified endometrial cancer, and 3,368 controls with an intact uterus. We used unconditional logistic regression to calculate odds ratios as estimates of relative risks. Results: Use of any sort of oral contraceptive decreased risk for endometrial cancer by 30%, while progestin-only pills reduced risk more markedly. For COCs the reduction in risk was noticeable following 3 or more years of use (OR 0.5, 95% CI 0.3-0.7), and increased with duration of intake, reaching 80% lower risk after 10 years of use. The protective effect of COC use was similar for all degrees of tumor differentiation and invasiveness, and remained for at least 20 years after cessation of use. Subsequent use of hormone replacement did not modify these protective effects. Conclusions: We conclude that COC use confers a long-lasting protection against endometrial cancer risk which is particularly marked for long-term users.
引用
收藏
页码:277 / 284
页数:8
相关论文
共 29 条
[1]   Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women [J].
Beresford, SAA ;
Weiss, NS ;
Voigt, LF ;
McKnight, B .
LANCET, 1997, 349 (9050) :458-461
[2]  
Breslow N.E., 1980, STAT METHODS CANC RE, P192
[3]   HORMONE REPLACEMENT THERAPY AND ENDOMETRIAL CANCER RISK - A METAANALYSIS [J].
GRADY, D ;
GEBRETSADIK, T ;
KERLIKOWSKE, K ;
ERNSTER, V ;
PETITTI, D .
OBSTETRICS AND GYNECOLOGY, 1995, 85 (02) :304-313
[4]   Physiological action of progesterone in target tissues [J].
Graham, JD ;
Clarke, CL .
ENDOCRINE REVIEWS, 1997, 18 (04) :502-519
[5]  
GRAY LA, 1977, OBSTET GYNECOL, V49, P385
[6]   ENDOMETRIAL CANCER - BIOCHEMICAL AND CLINICAL CORRELATES [J].
GURPIDE, E .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (06) :405-416
[7]   THE EPIDEMIOLOGY OF ENDOMETRIAL CANCER IN YOUNG-WOMEN [J].
HENDERSON, BE ;
CASAGRANDE, JT ;
PIKE, MC ;
MACK, T ;
ROSARIO, I ;
DUKE, A .
BRITISH JOURNAL OF CANCER, 1983, 47 (06) :749-756
[8]   PROGESTERONE ANTAGONISM OF ESTROGEN-RECEPTOR AND ESTROGEN-INDUCED UTERINE GROWTH [J].
HSUEH, AJW ;
PECK, EJ ;
CLARK, JH .
NATURE, 1975, 254 (5498) :337-339
[9]   PROTECTION AGAINST ENDOMETRIAL CARCINOMA BY COMBINATION-PRODUCT ORAL-CONTRACEPTIVES [J].
HULKA, BS ;
CHAMBLESS, LE ;
KAUFMAN, DG ;
FOWLER, WC ;
GREENBERG, BG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 247 (04) :475-477
[10]  
*INT AG RES CANC, 1999, IN PRESS IARC MON EV, V72